论文部分内容阅读
本研究采用聚合酶链反应（PCR）结合中性聚丙烯酰胺凝胶电泳和激光扫描技术，对38例卵巢癌、20例癌旁组织、4例卵巢良性上皮性肿瘤及2例正常卵巢组织进行myc基因家族检测，发现在卵巢癌组织中C－myc、N－myc、L－myc扩增率分别为47％、42％、42％。癌旁组织扩增率分别为40％、20％、40％。在淋巴结转移的10例卵巢癌标本中，C－myc与N－myc全部扩增，L－myc扩增只有2例，良性肿瘤及正常组织均未有扩增。结果还显示：L－myc和N－myc同时扩增占16％（6／38），N－myc和C－myc同时扩增占26％（10／38），而C－myc和L－myc同时扩增占16％（6／38），没有一例三种基因同时扩增。大多数扩增与临床分期、病理分化程度、淋巴结转移密切相关。
In this study, polymerase chain reaction (PCR) combined with neutral polyacrylamide gel electrophoresis and laser scanning technology, 38 cases of ovarian cancer, 20 cases of paracancerous tissues, 4 cases of ovarian benign epithelial tumors and 2 cases of normal ovarian tissue myc gene family test found that in ovarian cancer C-myc, N-myc, L-myc amplification rates were 47%, 42%, 42%. The rate of paracancerous tissue expansion was 40%, 20%, 40% respectively. In 10 cases of lymph node metastasis of ovarian cancer specimens, C-myc and N-myc all amplified, L-myc amplification in only 2 cases, no benign tumors and normal tissue amplification. The results also showed that simultaneous amplification of L-myc and N-myc accounted for 16% (6/38), simultaneous amplification of N-myc and C-myc accounted for 26% (10/38), while C-myc and L-myc At the same time amplification accounted for 16% (6/38), no case of three genes simultaneously amplified. Most of the amplification and clinical stage, pathological differentiation, lymph node metastasis are closely related.